Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects.
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects.
复制标题
钙通道阻滞剂治疗心血管疾病。
DOI：
10.1097/00003246-198412000-00025
复制
发表时间：
1980
影响因子：
39.2
通讯作者：
E. Braunwald
中科院分区：
文献类型：
--
作者：
E. Antman;P. Stone;J. Muller;E. Braunwald
钙离子在心血管系统中起着重要作用。它们参与电生理过程，将兴奋与肌肉收缩联系起来，控制能量储存和利用，并收缩冠状动脉和全身动脉中的血管平滑肌。已经开发出一组新的阻断钙离子穿过细胞膜的药理学试剂。这些药物在细胞去极化的缓慢内向电流期间起作用。最广泛的临床经验已获得四个这些药物：维拉帕米，硝苯地平，perhexiline，地尔硫卓。维拉帕米对慢内向电流有显著的电生理作用，正成为一种有价值的抗心律失常药物。折返性室上性心律失常，如阵发性室上性心动过速，特别适合静脉注射维拉帕米治疗。口服维拉帕米长期治疗控制房颤、房扑和阵发性室上性心动过速的初步试验表明，该药物对治疗这些心律失常有效。
Calcium ions play an important role in the cardiovascular system. They are involved in electrophysiologic processes, link excitation to muscular contraction, control energy storage and utilization, and constrict vascular smooth muscle in coronary and systemic arteries. A new group of pharmacologic agents that block the passage of calcium ions across cell membranes has been developed. These agents act during the slow inward current of cellular depolarization. The most extensive clinical experience has been obtained with four of these agents: verapamil, nifedipine, perhexiline, and diltiazem. Verapamil, which has profound electrophysiologic effects on the slow inward current, is emerging as a valuable antiarrhythmic agent. Re-entrant supraventricular arrhythmias, such as paroxysmal supraventricular tachycardia, are particularly amenable to treatment with intravenous verapamil. Preliminary trials of long-term therapy with oral verapamil for control of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia suggest that this agent is effective for therapy of these arrhythmias.